Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Bookmark and Share
Published: 30 May 2015
Views: 2914
Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada

Prof Margolese talks to ecancertv at ASCO 2015 about a federally funded phase III trial that suggests postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.

Read the news article and watch the press conference for more.